Keith Lamont Cummings - Jan 23, 2023 Form 4 Insider Report for PLIANT THERAPEUTICS, INC. (PLRX)

Signature
/s/ Mike Ouimette, attorney-in-fact
Stock symbol
PLRX
Transactions as of
Jan 23, 2023
Transactions value $
-$915,150
Form type
4
Date filed
1/25/2023, 08:00 PM
Previous filing
Dec 27, 2022
Next filing
Jan 27, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction PLRX Common Stock Options Exercise $26K +12.5K +14.81% $2.08* 96.9K Jan 23, 2023 Direct
transaction PLRX Common Stock Options Exercise $109K +17.5K +18.06% $6.22 114K Jan 23, 2023 Direct
transaction PLRX Common Stock Sale -$1.05M -30K -26.22% $35.00 84.4K Jan 23, 2023 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction PLRX Stock Option (right to buy) Options Exercise $0 -12.5K -8.56% $0.00 134K Jan 23, 2023 Common Stock 12.5K $2.08 Direct F2
transaction PLRX Stock Option (right to buy) Options Exercise $0 -17.5K -49.02% $0.00 18.2K Jan 23, 2023 Common Stock 17.5K $6.22 Direct F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on October 5, 2021, as amended on August 29, 2022.
F2 25% of the shares subject to such option vested on December 31, 2019 and 1/48th of the shares subject to the option vest in substantially equal monthly installments thereafter, subject to the Reporting Person's continuous service to the Issuer on each such date.
F3 1/48th of the shares subject to such option vest and become exercisable in substantially equal installments on each monthly anniversary of March 31, 2020 (or if there is no corresponding day in any such month, on the last day of such month), subject to the Reporting Person's continuous service to the Issuer on each such date.